Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The ...

Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to ...

Federal funding ensures that hemophilia treatment centers can properly care for those with bleeding disorders, columnist Jennifer Lynne says.

Hemophilia A patients with self-described problem joints were found to have worse clinical outcomes, with more pain, in a new study.

Novo Nordisk has shared positive results from a late-stage study of its investigational haemophilia A therapy Mim8 in ...

The data showed that Mim8 was well-tolerated and efficacious in children with haemophilia A with and without inhibitors. In part one of the FRONTIER3 study, participants with haemophilia A received ...

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated ...